osimertinib,tepotinib
merck,AstraZeneca
['lung', 'osimertinib']
in this study, our experts found dual egfr and met inhibition yielded high clinical response rate after progression on osimertinib for patients with egfr-mutant non-small cell lung cancer: #esmo22 #endcancer 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789